Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-379-7 | CAS number: 81-83-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: other routes
Administrative data
- Endpoint:
- short-term repeated dose toxicity: other route
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well documented study report which meets basic scientific principles (test substance purity not known).
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 984
- Report date:
- 1984
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Subacute toxicity (5 consecutive days) upon intravenous injection with 33-day observation period.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Benzisoquinolinedione
- IUPAC Name:
- Benzisoquinolinedione
- Details on test material:
- - Analytical purity: No data
- Lot/batch No.: B-1
- Storage condition of test material: room temperature
- Stability: The test article is stable at 60°C for 30 days. Additionally, aqueous solutions of Benzisoquinolinedione are stable at room temperature for 14 days. Results by infrared and ultraviolet spectroscopy indicated that the test article did not decompose under the storage conditions.
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: Charles River CD2F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Animal Genetics and Production Branch, DTP, DCT, NCI
- Age at study initiation: < 8 weeks
- Weight at study initiation: 18.3 to 22.5 g for males and 16.6 to 22.0 g for females (Weight range of females was out of the protocol range of 17.0 - 23.0 g for this sex. Weight ranges within each sex were 4.2 g for males und 5.4 g for females which were out of the protocol 4 gram range within each sex.)
- Housing: group housed by dose and separated by sex with five mice per cage
- Diet: ad libitum (Purine Certified Rodent Chow)
- Water: ad libitum (tap water)
- Acclimation period: for a minimum of one week
ENVIRONMENTAL CONDITIONS
- Temperature: 21°C
- Humidity (%): 32.1% ± 1.3% (range: 13 - 61%)
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- other: 0.9% sterile saline with hydrochloric acid (0.5 N)
- Details on exposure:
- Dosing solutions were prepared by diluting an initially prepared stock solution of 50 mg/mL of the test item in vehicle until obtaining the targeted test concentrations. The dosing preparations were formulated on day 1 of treatment and were stored at room temperature. A sample of each dosing preparation was taken for concentration analysis. One dosing preparation was selected, at random, for homogeneity analysis. Homogeneity analysis consisted of concentration analysis of a top, middle, and bottom portion of the solution. Concentration analyses were performed by means of high performance liquid chromatography (HPLC).
The lateral tail vein was used for all injections. To facilitate doing, mice were placed in a restrainer with the tail exposed. A lighted box was placed under the mouse with the light shining through a sIit where the mouse's tail was situated. lnjections were completed in approximately 4 seconds. The volume of injection was 0.015 mL/g body weight for all dose groups. The highest concentration used in the study was 3.93 mg/mL. - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 5 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
17, 21, 26, 32, 39, 48, 59 mg/kg bw (all within 7% of the theoretical concentrations; additionally, homogeneity tests show homogeneity of the dosing preparations)
- No. of animals per sex per dose:
- 15 (Due to dosing difficulty, one male of the 48 mg/kg bw group was taken off the study on day 5.)
- Control animals:
- other: vehicle control and nontreated control group
- Details on study design:
- - Post-exposure period: 33 days
Examinations
- Observations and examinations performed and frequency:
- DEATH AND CLINICAL SIGNS: daily
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were taken for all surviving mice on days 1 - 5, 12, 19, 26 and 33.
Results and discussion
Results of examinations
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
100% mortality was observed in both males and females at the doses of 59.0, 48.0 and 39.0 mg/kg bw and in females at the dose of 32.0 mg/kg bw. No deaths occurred in either sex at the doses of 21.0 und 17.0 mg/kg bw. In general, the higher the dose, the earlier the mortality. Probit results for days 7, 14 and 33 are: on day 7, LD10, LD50 und LD90 were 27.5, 35.0 und 44.6 mg/kg bw for males, 29.3, 47.2 und 76.2 mg/kg bw for females, and 27.2, 40.4 und 60.0 mg/kg bw for the combined sexes. Due to slightly later deaths in females, lethality doses in this sex were slightly higher than those in males on day 7. Since all the deaths occurred between days 2 und 10, probit values were the same for days 14 and 33. On these two days, lethality doses in females could not be calculated because there was only one data point which was neither 0% nor 100% mortality. On days 14 and 33, LD10, LD50 and LD90 were 24.3, 28.12 and 34.2 mg/kg bw for males and 24.9, 28.4 und 32.5 mg/kg bw for the combined sexes. Based on the probit results in males and combined sexes, there was no apparent sex difference in the final lethality doses.
Drug-related clinical signs observed, in the order of frequency, were rough hair coat, decreased activity, dehydration, hunched posture, labored breathing, loss of locomotor activity, exophthalmus, necrotic and/or swollen tails, ataxia, swollen face and eyes closed with discharge. No drug-related clinical signs were observed at the two lowest doses of 21.0 and 17.0 mg/kg bw. Clinical signs of labored breathing, loss of locomotor ability and exophthalmus occurred immediately or shortly after dosing. ClinicaI signs of death, rough hair coat, decreased activity and hunched posture occurred either shortly after dosing or as long as a few days after dosing. ClinicaI signs of dehydration, necrotic and/or swollen tails, moribundity, ataxia, swollen face and eyes closed with discharge had late occurrences. Drug-related clinical signs were dose-related and males and females were similarly affected. All other observations were considered to be non-drug-related.
BODY WEIGHT AND WEIGHT GAIN:
The test substance caused a dose-related slight to severe weight loss (6% to 15%) from days 1 to 5 in both sexes at the four highest doses of 59.0, 48.0, 39.0 and 32.0 mg/kg bw. From days 1 to 5, males and females at the three lowest doses of 26.0, 21.0 and 17.0 mg/kg bw also had a slower weight gain than that of the control groups. A further weight loss, although very slight, was observed from days 5 to 12 in males treated with 32.0 mg/kg bw and in females treated with 26.0 mg/kg bw, while the remaining surviving dose/sex groups had a substantial weight gain from days 5 to 12. A normal to substantial weight gain was observed in all dose/sex groups from days 12 to 19. Mean body weights of the surviving dose/sex groups were comparable to the controls on days 26 and 33.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
- Dose descriptor:
- other: LD50
- Effect level:
- 28.4 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: Mortality
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.